NYSE: HAE · Medical Devices

Haemonetics (HAE) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Haemonetics (HAE) at $120.83 a share. The stock last closed at $121.34, which puts the model's fair value 0.4% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Haemonetics Corporation.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$120.83midpoint of 2,000 simulations
Last close$121.34NYSE: HAE
Gap to fair value-0.4%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $116.81 to $120.83 (+3.4%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.

What the model makes of itThe price of $121.34 is level with it: Fairly valued, on a medium evidence grade.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 10% either way over the next month. On the model's Quality Momentum list since 21 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give HAE?

The calibrated range for HAE over 63 trading days is $108.00 to $137.13. It sits around the last close, and its width comes from the volatility that HAE's own options imply (35% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $90.25 to $159.35. In 48% of the simulations the fair value came out above the price the model ran on.

$60.58$229.52
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $120.83. Dashed line: the last close, $121.34.

Faircurve Insights · 14 Nov 2026

Haemonetics Corporation (HAE) is a healthcare enterprise that provides medical products and comprehensive solutions. Its three main business areas are Plasma, Blood Center and Hospital.

Faircurve's model put the fair value at $120.83 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $116.81, so the fair value moved +3.4%. The model's reason: analysts raised their next-twelve-month EBITDA estimates, which was most of the move. The calibrated range over 63 trading days is $109.38 to $139.00. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations. The evidence grade is Medium. It looks at input completeness, the number and agreement of comparable companies and the width of outcomes. It does not say whether the fair value is right.

The business scores 71 out of 100 on the model's overall quality score, a composite of six factors measured against comparable companies. Earnings quality scores 100, with FCF / net income at 2.92x. Capital discipline scores 85, with net buybacks at 1.8% of market value against a peer median of 0.1%. Profitability scores 76, with ROIC at 10.5% against a peer median of 3.2%. The model compares Haemonetics with ten companies, including LivaNova PLC (LIVN) and Align Technology, Inc. (ALGN).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does HAE report earnings, and how has the stock reacted?

Haemonetics's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 8.2% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. HAE's 30 day implied volatility works out to about 10.2% over one month.

How HAE moved around its last 8 earnings reports

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 10.9%.

Report dateTwo session move
5 Nov 2026-5.9%
6 Aug 2026+5.1%
7 May 2026+4.7%
5 Feb 2026-10.0%
6 Nov 2025+34.8%
7 Aug 2025-28.7%
6 Feb 2025-16.7%
7 Nov 2024+11.8%

What the options market has priced for a month's move in HAE

5%10%15%20%5 Nov '26 report10% at 16 Nov '2624 Sep '2616 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 11% on 24 Sep 2026, reached 18% on 30 Oct 2026 and reads 10% on 16 Nov 2026. The marks are report dates.

How does HAE score on business quality?

Haemonetics's overall quality score is 71 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.7610.5%ROIC3.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).1002.92xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.46-2.0%Revenue growth, trailing8.4%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.851.8%Net buybacks / market value0.1%
Balance sheetNet debt to EBITDA and interest coverage.333.11xNet debt / EBITDA1.95x
StabilityDownside volatility of the EBITDA margin over the last five years.671.4 ptsEBITDA margin downside volatility, 5y1.5 pts

How does HAE compare with similar companies?

The companies in medical devices closest to Haemonetics in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
LIVN LivaNova PLC$92.44$101.82+10.1%Fairly valued
ITGR Integer Holdings Corporation$126.97$153.83+21.2%Undervalued
BRKR Bruker Corporation$60.62$64.27+6.0%Fairly valued
GMED Globus Medical, Inc.$70.50$76.21+8.1%Fairly valued
BIO Bio-Rad Laboratories, Inc.$360.26$340.60-5.5%Fairly valued
TMDX TransMedics Group, Inc.$92.21$102.39+11.0%Fairly valued
PODD Insulet Corp.$145.29$158.48+9.1%Fairly valued
ALGN Align Technology, Inc.$165.98$200.67+20.9%Undervalued

What the comparable companies' multiples alone would give for HAE, the peer-implied price, is $107.04 a share on this run. The fair value weighs that against the company's own multiple.

All medical device stocks ranked by gap to fair value

Haemonetics at a glance

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital.

Market value
$5.6B
Sector
Healthcare
Industry
Medical Devices
Revenue expected, next twelve months
$1.5B
Consensus revenue growth, next fiscal year
+8.0%
Analysts with estimates
8
Beta to the US market
0.12
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. HAE was not among them.

How the fair value is worked out: the model prices Haemonetics on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for HAE was $116.81. As of 14 Nov 2026 it is $120.83, a change of +3.4%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Haemonetics's valuation

Is Haemonetics stock undervalued or overvalued?

On Faircurve's model, HAE reads as Fairly valued as of 14 Nov 2026. The model's fair value is $120.83 a share against a last close of $121.34, a gap of -0.4%.

What is HAE's fair value?

$120.83 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $90.25 to $159.35.

What price range does the model give HAE?

$108.00 to $137.13 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Haemonetics report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has HAE moved on past earnings reports?

Across its last 8 reports the median two session move was 10.9%, ignoring direction. The largest was +34.8% around the report of 6 Nov 2025.

How confident is the model in this valuation?

The model's evidence grade for HAE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on HAE

The model has an idea open on HAE under Quality Momentum since 21 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on HAE with their outcomes. A free account is enough.

Keep reading